Stromal herpetic keratitis has a poor prognosis. To date, corticosteroids appear to be the most efficatious agents against the condition. However, corticosteroids are immuno6uppresive, and may cause recurrences. The recent findings of decreased cellular immunity in the condition offer the possibility of using levamisole as the therapeutic agent. The present investigation was undertaken to evaluate the clinical effects of levamisole on the twenty-one patients with stromal herpetic keratitis. Results were favorable in sixteen. The side effects of levamisole were relatively mild and transient. The results of the present study confirm the efficacy and safety of levamisole for the treatment of stromal herpetic keratitis.